Evidence map›Paper›PMID 41518400›Full record

Trial reportEuropean journal of nuclear medicine and molecular imaging2026

Preclinical and preliminary clinical evaluation of [

Yuying Li, Meijie Pan, Haonan Yu, Qilei Zhang, Yan Chang, Hailong Zhao, Jiaqi Wang, Xiaoming Wang, Jiapei Dai, Lu Yu and 5 more

2 registry-linked trialsAbstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06593626 phase1completednot on this map

A Phase I Clinical Study on the Safety and Pharmacokinetics of [18F]Florbetazine Injection in Healthy Subjects and Patients With Amyloid Fibrils

TypeinterventionalSponsorHTA Co., Ltd.Ran2023 to 2025Enrolled28ConditionsMCI, ADArms[18F]Florbetazine
NCT06725706 recruitingnot on this map

Beta Amyloid PET/CT in Various Aβ-Related Disease

Typeobservational_patient_registrySponsorTianjin Medical UniversityRan2012 to 2027Enrolled500ConditionsAmyloid, Beta-Amyloid, Neurodegenerative DiseasesArms18F-92/AV45, 11C-PIB
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yuying Li *Key Laboratory of Radiopharmaceuticals, Ministry of Education, Beijing Normal University, Beijing, 100875, China.
Meijie Pan *Department of PET/CT Diagnostic, Tianjin Medical University General Hospital, Tianjin, 300052, China.
Haonan YuDepartment of PET/CT Diagnostic, Tianjin Medical University General Hospital, Tianjin, 300052, China.
Qilei ZhangDepartment of Anatomy and Neurobiology, Xiangya School of Medicine, Central South University, Changsha, 410013, China.
Yan ChangDepartment of Nuclear Medicine, Chinese PLA General Hospital, Beijing, 100853, China.
Hailong ZhaoHighTech Atom Co., Ltd, Beijing, 102413, China.
Jiaqi WangDepartment of Pathology, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, China.
Xiaoming WangHighTech Atom Co., Ltd, Beijing, 102413, China.
Jiapei DaiWuhan Institute for Neuroscience and Neuroengineering, South-Central Minzu University, Wuhan, 430074, China.
Lu YuDepartment of Pathology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.
Dong ChenDepartment of Pathology, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, China. azchendong@163.com.
Jinming ZhangDepartment of Nuclear Medicine, Chinese PLA General Hospital, Beijing, 100853, China.
Xiao-Xin YanDepartment of Anatomy and Neurobiology, Xiangya School of Medicine, Central South University, Changsha, 410013, China.
Shaobo YaoDepartment of PET/CT Diagnostic, Tianjin Medical University General Hospital, Tianjin, 300052, China. yaoshaobo008@163.com.
Mengchao CuiKey Laboratory of Radiopharmaceuticals, Ministry of Education, Beijing Normal University, Beijing, 100875, China. cmc@bnu.edu.cn.ORCID 0000-0002-3488-7864

Funding

National Natural Science Foundation of China 22022601National Natural Science Foundation of China 22306015National Natural Science Foundation of China 22376016Science Innovation 2030-Brain Science and Brain-Inspired Intelligence Technology Major Projects 2021ZD0201103Science Innovation 2030-Brain Science and Brain-Inspired Intelligence Technology Major Projects 2021ZD0201803
6 · The paper itself

Abstract

purposeEarly detection of cardiac amyloidosis (CA) remains challenging, and a PET tracer capable of directly visualizing amyloid deposits could improve diagnosis. Given the shared β-sheet structure of amyloid deposits in CA and Alzheimer's disease (AD), this study aimed to evaluate the suitability of the AD amyloid tracer [

methodsSpecific binding and affinity of [

resultsAutoradiography confirmed specific binding of [

conclusionsThese integrated preclinical and preliminary clinical evaluation demonstrates that [

trial registrationClinical trial registry NCT06593626 (registered 24 May 2024) and NCT06725706 (registered 5 Dec 2024).

Indexed as

AmyloidosisAniline CompoundsCardiomyopathiesPositron Emission Tomography Computed TomographyAgedAnimalsFemaleHumansMaleMiddle AgedRadiopharmaceuticalsRatsRats, Sprague-DawleyStilbenesTissue Distribution4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbeneAniline CompoundsRadiopharmaceuticalsStilbenes[18F]FlorbetazineAutoradiographyCardiac amyloidosisPET imaging

Identifiers

PMID41518400

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.